Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 22:8:1592.
doi: 10.3389/fmicb.2017.01592. eCollection 2017.

Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches

Viola C Scoffone  1 , Laurent R Chiarelli  1 , Gabriele Trespidi  1 , Massimo Mentasti  2   3 , Giovanna Riccardi  1 , Silvia Buroni  1
Affiliations
Review

Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches

Viola C Scoffone et al. Front Microbiol. .

Abstract

Burkholderia cenocepacia is an opportunistic pathogen particularly dangerous for cystic fibrosis (CF) patients. It can cause a severe decline in CF lung function possibly developing into a life-threatening systemic infection known as cepacia syndrome. Antibiotic resistance and presence of numerous virulence determinants in the genome make B. cenocepacia extremely difficult to treat. Better understanding of its resistance profiles and mechanisms is crucial to improve management of these infections. Here, we present the clinical distribution of B. cenocepacia described in the last 6 years and methods for identification and classification of epidemic strains. We also detail new antibiotics, clinical trials, and alternative approaches reported in the literature in the last 5 years to tackle B. cenocepacia resistance issue. All together these findings point out the urgent need of new and alternative therapies to improve CF patients' life expectancy.

Keywords: Burkholderia cenocepacia; antibiotics; epidemiology; new therapies; resistance.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Summary of the new therapies and approaches described in the review. (A) The current approaches utilized in clinical practice; (B) new alternatives.
See this image and copyright information in PMC

References

    1. Aktaş Z., Kayacan C., Oncul O. (2012). In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39 86–89. 10.1016/j.ijantimicag.2011.09.012 - DOI - PubMed
    1. Alexander B. D., Petzold E. W., Reller L. B., Palmer S. M., Davis R. D., Woods C. W., et al. (2008). Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am. J. Transplant. 8 1025–1030. 10.1111/j.1600-6143.2008.02186.x - DOI - PubMed
    1. Alisky J., Iczkowski K., Rapoport A., Troitsky N. (1998). Bacteriophages show promise as antimicrobial agents. J. Infect. 36 5–15. 10.1016/S0163-4453(98)92874-2 - DOI - PubMed
    1. Allison K. R., Brynildsen M. P., Collins J. J. (2011). Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr. Opin. Microbiol. 14 593–598. 10.1016/j.mib.2011.09.002 - DOI - PMC - PubMed
    1. Amato D. N., Amato D. V., Mavrodi O. V., Braasch D. A., Walley S. E., Douglas J. R., et al. (2016). Destruction of opportunistic pathogens via polymer nanoparticle-mediated release of plant-based antimicrobial payloads. Adv. Healthc. Mater. 5 1094–1103. 10.1002/adhm.201500974 - DOI - PMC - PubMed

LinkOut - more resources